Yatharth Hospital & Trauma Care Services has scheduled an Extraordinary General Meeting for October 15, 2026, to secure shareholder approval for a Rs 3,150 crore capital infusion from Rasmalai Limited, an affiliate of global private equity giant Advent International. The deal involves issuing over 3 crore securities at Rs 985.17 each, significantly bolstering the company’s expansion and debt reduction roadmap while granting the investor substantial governance rights and board representation.
Yatharth Hospital Announces Rs 3,150 Crore Preferential Issue to Advent Affiliate
Total consideration of Rs 3,150 crore is expected; post-issue, the investor will hold a 24.87% stake.
Reader Takeaway: This capital boost enables rapid expansion and debt reduction, though it introduces new governance rights for the investor.
What just happened
Yatharth Hospital & Trauma Care Services has called for an EGM on October 15, 2026. The agenda focuses on a massive preferential issue of equity shares and warrants to Rasmalai Limited, a Cyprus-based entity under the Advent International umbrella. The company intends to issue 1,30,26,516 equity shares and 1,89,47,664 warrants at a fixed price of Rs 985.17 per security. This influx of capital will increase the company’s authorized share capital from Rs 115 crore to Rs 150 crore.
Why this matters
This deal serves as a dual-purpose catalyst: it injects Rs 2,362.50 crore into hospital infrastructure, working capital, and debt repayment, while earmarking Rs 787.50 crore for general corporate purposes. Beyond the cash, the deal significantly alters the governance structure. Rasmalai Limited will receive rights to nominate directors and hold veto power over specific reserved matters, signaling a deep integration of private equity management standards into the company’s board operations.
What changes now
The company is amending its Articles of Association to reflect these new investor and promoter rights. Additionally, an "Upside Share Arrangement" is being introduced, which allows promoters to share in a portion of the profit pool upon an investor exit, provided specific return thresholds are met. This mechanism is structured as an investor-funded incentive and is noted as having no financial cost to the company itself.
Risks to watch
The completion of the issuance is subject to necessary approvals, most notably from the Competition Commission of India (CCI). Any delay in regulatory clearance or friction in the integration of investor-mandated board committees could impact the timeline of the capital deployment.
What to track next
Shareholders should monitor the outcomes of the EGM vote and subsequent filings regarding the official receipt of the Competition Commission of India clearance. Additionally, updates regarding the phased exercise of the warrants will indicate the company's long-term capital stability.